Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?
Soe NaingGeeta RameshJasmine GarchaAnupama PoliyedathStutee KhandelwalPaul K MillsPublished in: Endocrinology, diabetes & metabolism (2020)
De-escalating from AIT to the combined use of metformin, SGLT2i, GLP1 RA and basal insulin in obese patients with poorly controlled T2DM on MDI resulted in significant improvement in glycaemic control, weight loss and significantly higher patient satisfaction. This stepping-down approach may be the better option than continuing MDI in these patients.
Keyphrases
- type diabetes
- weight loss
- glycemic control
- patient satisfaction
- end stage renal disease
- bariatric surgery
- newly diagnosed
- insulin resistance
- chronic kidney disease
- metabolic syndrome
- adipose tissue
- ejection fraction
- rheumatoid arthritis
- physical activity
- stem cells
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- obese patients
- gastric bypass
- patient reported outcomes
- bone marrow
- disease activity
- ultrasound guided
- medical education